Steven Cohen Denali Therapeutics Inc. Transaction History
Point72 Asset Management, L.P.
- $42.2 Billion
- Q4 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 548,739 shares of DNLI stock, worth $11.4 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
548,739
Previous 333,530
64.52%
Holding current value
$11.4 Million
Previous $9.72 Million
15.11%
% of portfolio
0.03%
Previous 0.03%
Shares
8 transactions
Others Institutions Holding DNLI
# of Institutions
241Shares Held
121MCall Options Held
80KPut Options Held
36.8K-
Black Rock Inc. New York, NY13.2MShares$273 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$255 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$249 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$204 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.48MShares$114 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.78B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...